Bibliography
- EHLERT JE: Chemokines and chemokine receptors: disease targets for therapeutic development. Expert Opin. Investig. Drugs (2000) 9:627–629.
- •Good review of the therapeutic potential of chemokine antagonism.
- ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol ScL (2002) 23:459–467.
- ••Very useful recent review of the literaturein this field.
- NORMAN P: Developing anti-inflammatory drugs for the treatment of COPD. Inflation. Res. in press.
- •Up-to-date overview of approaches to the treatment of inflammation in COPD.
- JIE JL: Small molecule interleukin-8 modulators. Expert Opin. Ther. Patents (2001) 11:1905–1910.
- ••Recent review of CXCRI and 2antagonists, and the patent literature.
- TRAVES SL, SMITH SJ, BARNES PJ, DONNELLY LE: Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. Leukoc. Biol. in press.
- •Suggestive that the CXCR2 receptor is the more pertinent target.
- WHITE JR, LEE JM, YOUNG PR et al.: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.j Biol. Chem. (1998) 273:10095–10098.
- WIDDOWSON KL, ELLIOTT JD, VEBER DF et al.: Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. I Med. Chem. (2004) 47:1319–1321.
- BAXTER A, BENNION C, BENT J et al.: Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:2625–2628.